Insmed Incorporated (INSM) — Stock Score Summary

Insmed Incorporated (INSM) has a MoatMap StockRank of 7/100 based on Quality (27/100), Value (33/100), and Momentum (26/100) factor scores. The current signal is STRONG SELL. While Insmed has promising clinical assets like brensocatib, it remains a highly volatile, unprofitable biotech company that does not meet our strict quality compounder criteria.

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing innovative treatments for serious and rare diseases, with a primary focus on pulmonary conditions such as NTM lung disease. The company's competitive moat is anchored by its approved orphan drug, ARIKAYCE, addressing a high unmet medical need, supported by a specialized commercial infrastructure and a promising pipeline of rare disease candidates. Insmed operates as a targeted leader in its niche, striving to improve outcomes for patients with devastating and underserved conditions.

Key Financial Metrics

Price$99.04
Market Cap$23.5B
P/E (Forward)259.68
Price/Book32.23
Return on Equity-294.5%
Return on Invested Capital-66.5%
Debt/Equity105.34
Gross Margin81.8%
Operating Margin-65.5%
Revenue Growth229.6%
Free Cash Flow$-606M

Insmed Incorporated operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Insmed Incorporated’s (INSM) StockRank?
MoatMap’s StockRank for Insmed Incorporated (INSM) is 7/100, with a Strong Sell signal. It is a composite of Quality (27), Value (33), and Momentum (26) factor ranks across MoatMap’s 19,000+ stock universe.
Does Insmed Incorporated have an economic moat?
Insmed Incorporated (INSM) has a Quality factor score of 27/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Insmed Incorporated a buy, hold, or sell?
MoatMap’s current signal for Insmed Incorporated (INSM) is Strong Sell, based on a StockRank of 7/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Insmed Incorporated in?
Insmed Incorporated (INSM) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksINSM deep dive reportAI ChampionsHow we score stocksSense-check another stock